PRA announced it has completed its 20th first in human trial with biologics.
PRA announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience. Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.